<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166398</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-UNSD-101</org_study_id>
    <nct_id>NCT02166398</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers</brief_title>
  <acronym>UI15AML055MT</acronym>
  <official_title>Phase 1 Study of Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, two-way crossover clinical trial to compare the
      safety, pharmacokinetic profiles of UI15AML055MT and Amosartan® tablet 5/50 mg after a single
      oral administration in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, two-way crossover clinical trial to compare the
      safety, pharmacokinetic profiles of UI15AML055MT and Amosartan® tablet 5/50 mg after a single
      oral administration in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Amlodipine</measure>
    <time_frame>1d,15d 0h pre-dose, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Losartan</measure>
    <time_frame>1d,15d 0h pre-dose, 0.25, 0.5, 0.75, 1, 1.25 1.5, 2, 3, 4, 6, 8, 10, 12h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amosartan 5/50 tab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amosartan 5/50 tab given by oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UI15AML055MT tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UI15AML055MT tab given by oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UI15AML055MT</intervention_name>
    <description>tab, PO</description>
    <arm_group_label>UI15AML055MT tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amosartan 5/50</intervention_name>
    <description>tab, PO</description>
    <arm_group_label>Amosartan 5/50 tab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 20 under 45 years of age

          -  BMI state over 19 under 27

        Exclusion Criteria:

          -  mean sit SBP≥100mmHg or mean sit DBP≥150mmHg at screening

          -  mean sit SBP≥65mmHg or mean sit DBP≥95mmHg at screening

          -  Patients showed clinically significant hematological finding, patients with renal
             diseases (serum creatinine), patients with hepatic disease (ALT or AST)

          -  History of alcohol or drug abuse

          -  Positive to pregnancy test, nursing mother, has an intention on pregnancy

          -  Considered by investigator as not appropriate to participate in the clinical study
             with othe reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amlodipine basylate, Losartan potassium</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

